Drug Trial Radar · NCT02059564
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Feb 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
44
Planned (sponsor's estimate)
Start
Dec 2013
Primary completion
Oct 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects with Type 2 Diabetes Mellitus
Conditions
- Diabetes Mellitus
Interventions
HM11260CDrug
doses of 6 mg, 16 mg
PlaceboDrug
Normal saline solution
VictozaDrug
doses of 1.8 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK profile of acetaminophenTime frame: 13 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hanmi
California City, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.